Kanagawa, Japan

Kazuyoshi Aso


Average Co-Inventor Count = 12.8

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
6 patents (USPTO):

Title: Kazuyoshi Aso: Innovator in Macrocyclic Compounds

Introduction

Kazuyoshi Aso is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of macrocyclic compounds. With a total of 6 patents, Aso's work focuses on innovative solutions for various health-related issues.

Latest Patents

Aso's latest patents include the development of macrocyclic compounds as proteasome inhibitors. These compounds are represented by specific formulas where the substituents R, R', R'', X, Y, and Z are defined in detail. The applications of these compounds are extensive, as they are utilized in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases, inflammatory disorders, and muscular dystrophy. Additionally, they provide immunosuppression for transplanted organs or tissues.

Career Highlights

Throughout his career, Kazuyoshi Aso has worked with esteemed institutions such as Cornell University and the Tri-Institutional Therapeutics Discovery Institute. His research has significantly advanced the understanding and treatment of various diseases through innovative chemical compounds.

Collaborations

Aso has collaborated with notable colleagues, including Michael Andrew Foley and Wenhu Zhan. These partnerships have further enriched his research and contributed to the success of his inventions.

Conclusion

Kazuyoshi Aso's contributions to the field of medicinal chemistry through his innovative macrocyclic compounds have the potential to impact the treatment of numerous health conditions. His work exemplifies the importance of research and collaboration in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…